Palliative treatment of metastatic bone pain with radiopharmaceuticals: a perspective beyond Strontium-89 and Samarium-153

• Tipo: Artigo em Revista Científica Internacional
• Data: 2016

Autores

Francisco D. C. Guerra Liberal (Autor) FEUP; Adriana Alexandre S. Tavares (Autor) FEUP; João Manuel R. S. Tavares (Autor) FEUP

Revista

Título: Applied Radiation and Isotopes

Vol. 110

Páginas: 87-99

ISSN: 0969-8043

Editora: Elsevier

Indexação

ISI Web of Knowledge - 10 Citações

ISI Web of Science

Scopus - 23 Citações

Classificação Científica

CORDIS: Ciências Tecnológicas

FOS: Ciências médicas e da saúde

Outras Informações

ID Authenticus: P-00K-233

DOI: 10.1016/j.apradiso.2016.01.003

Abstract (EN): Purpose The present review article aims to provide an overview of the available radionuclides for palliative treatment of bone metastases beyond 89Sr and 153Sm. In addition, it aims to review and summarize the clinical outcomes associated with the palliative treatment of bone metastases using different radiopharmaceuticals. Materials and methods A literature search was conducted on Science Direct and PubMed databases (1990 - 2015). The following search terms were combined in order to obtain relevant results: ¿bone¿, ¿metastases¿, ¿palliative¿, ¿care¿, ¿therapy¿, ¿treatment¿, ¿radiotherapy¿, ¿review¿, ¿radiopharmaceutical¿, ¿phosphorus-32¿, ¿strontium-89¿, ¿yttrium-90¿, ¿tin-117m¿, ¿samarium-153¿, ¿holmium-166¿, ¿thulium-170¿, ¿lutetium-177¿, ¿rhenium-186¿, ¿rhenium-188¿ and ¿radium-223¿. Studies were included if they provided information regarding the clinical outcomes. Results and conclusions A comparative analysis of the measured therapeutic response of different radiopharmaceuticals, based on previously published data, suggests that there is a lack of substantial differences in palliative efficacy among radiopharmaceuticals. However, when the comparative analysis adds factors such as patient¿s life expectancy, radionuclides¿ physical characteristics (e.g. tissue penetration range and half-life) and health economics to guide the rational selection of a radiopharmaceutical for palliative treatment of bone metastases, 177Lu and 188Re-labeled radiopharmaceuticals appear to be the most suitable radiopharmaceuticals for treatment of small and medium/large size bone lesions, respectively.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 13